COVID-19 is a community acquired pneumonia caused by infection with a novel coronavirus, SARS CoV2 and is a serious condition with high mortality in hospitalised patients, for which there is no currently approved treatment other than supportive care. Urgent investigation of potential treatments for this condition is required.
This protocol describes an overarching and adaptive trial designed to provide safety, pharmacokinetic (PK)/ pharmacodynamic (PD) information and exploratory biological surrogates of efficacy which may support further development and deployment of candidate therapies in larger scale trials of COVID-19 positive patients receiving normal standard of care.
Given the spectrum of clinical disease, community based infected patients or hospitalised patients can be included. Products requiring parenteral administration will only be investigated in hospitalised patients. Patients will be divided into cohorts, a) community b) hospitalised patients with new changes on a chest x-ray (CXR) or a computed tomography (CT) scan or requiring supplemental oxygen and c) hospitalised requiring assisted ventilation. Participants may be recruited from all three of these cohorts, depending on the experimental therapy, its route of administration and mechanism of action. The relevant cohort(s) for any given therapy will be detailed in the therapy-specific appendix.
Candidate therapies can be added to the protocol and previous candidates removed from further investigation as evidence emerges. The trial will be monitored by an independent Data Monitoring Committee (DMC) to ensure patient safety.
Each candidate cohort will include a small cohort of patients randomised to candidate therapy or existing standard of care management dependent on disease stage at entry. Cohort numbers will be defined in the protocol appendices.
This is a Phase IIa experimental medicine trial and as such formal sample size calculations are not appropriate.

开始日期2020-07-03

申办/合作机构

The University of Edinburgh

[+3]

NCT03832946 / Completed临床2期

GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor Administered Via a Dry Powder Inhaler Over 52 Weeks

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.

开始日期2019-02-19

申办/合作机构

Galecto Biotech ApS

[+2]

NCT02257177 / Completed临床1/2期

A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This study will be divided into 2 parts. Part 1 is a randomized, double-blind, single centre, placebo-controlled, single ascending dose (SAD) phase I study designed to assess the safety, tolerability, PK and PD (Pharmacodynamic) of TD139 in up to 36 healthy male subjects. Part 2 will be a randomized, double-blind, multi-centre, placebo-controlled, multiple dose expansion cohort, designed to assess the safety, tolerability, PK and PD of TD139 in up to 24 male subjects and female subjects of non child-bearing potential with IPF.

开始日期2014-09-01

申办/合作机构

Galecto Biotech ApS

100 项与 Olitigaltin 相关的临床结果

登录后查看更多信息

100 项与 Olitigaltin 相关的转化医学

登录后查看更多信息

100 项与 Olitigaltin 相关的专利（医药）

登录后查看更多信息

项与 Olitigaltin 相关的文献（医药）

2024-07-01·Experimental Neurology

Galectin-3 modulates microglial activation and neuroinflammation in early brain injury after subarachnoid hemorrhage

Article

作者: Lu, Hua ; Lin, Chao ; Li, Zheng ; Ma, Chencheng ; Liu, Ning ; Zhang, Guangjian ; Zhang, Weiwei ; Mao, Lei ; Shen, Yuqi ; Chang, Hanxiao

BACKGROUNDAneurysmal subarachnoid hemorrhage (SAH) is a devastating acute cerebrovascular event with high mortality and permanent disability rates. Higher galectin-3 levels on days 1-3 have been shown to predict the development of delayed cerebral infarction or adverse outcomes after SAH. Recent single-cell analysis of microglial transcriptomic diversity in SAH revealed that galectin could influence the development and course of neuroinflammation after SAH.METHODSThis study aimed to investigate the role and mechanism of galectin-3 in SAH and to determine whether galectin-3 inhibition prevents early brain injury by reducing microglia polarization using a mouse model of SAH and oxyhemoglobin-treated activation of mouse BV2 cells in vitro.RESULTSWe found that the expression of galectin-3 began to increase 12 h after SAH and continued to increase up to 72 h. Importantly, TD139-inhibited galectin-3 expression reduced the release of inflammatory factors in microglial cells. In the experimental SAH model, TD139 treatment alleviated neuroinflammatory damage after SAH and improved defects in neurological functions. Furthermore, we demonstrated that galectin-3 inhibition affected the activation and M1 polarization of microglial cells after SAH. TD139 treatment inhibited the expression of TLR4, p-NF-κB p65, and NF-κB p65 in microglia activated by oxyhemoglobin as well as eliminated the increased expression and phosphorylation of JAK2 and STAT3.CONCLUSIONThese findings suggest that regulating microglia polarization by galectin-3 after SAH to improve neuroinflammation may be a potential therapeutic target.

2024-03-01·Brain, Behavior, and Immunity

Injured sensory neurons-derived galectin-3 contributes to neuropathic pain via programming microglia in the spinal dorsal horn

Article

作者: Ji, Luyao ; Xu, Kangtai ; Zeng, Qian ; Jiang, Changyu ; Wang, Zilong ; Wu, Yifei ; Chen, Yiming ; Xu, Yuanfan ; Liu, Yaqi ; Wu, Chaoran ; Hu, Qiaodan ; Li, Yitong ; Li, Changlin ; Wu, Jiawei ; Luo, Yuhui ; Shan, Leyan

Emerging studies have demonstrated spinal microglia play a critical role in central sensitization and contribute to chronic pain. Although several mediators that contribute to microglia activation have been identified, the mechanism of microglia activation and its functionally diversified mechanisms in pathological pain are still unclear. Here we report that injured sensory neurons-derived Galectin-3 (Gal3) activates and reprograms microglia in the spinal dorsal horn (SDH) and contributes to neuropathic pain. Firstly, Gal3 is predominantly expressed in the isolectin B4 (IB4)-positive non-peptidergic sensory neurons and significantly up-regulated in dorsal root ganglion (DRG) neurons and primary afferent terminals in SDH in the partial sciatic nerve ligation (pSNL)-induced neuropathic pain model. Gal3 knockout (Gal3 KO) mice showed a significant decrease in mechanical allodynia and Gal3 inhibitor TD-139 produced a significant anti-allodynia effect in the pSNL model. Furthermore, pSNL-induced microgliosis was compromised in Gal3 KO mice. Additionally, intrathecal injection of Gal3 produces remarkable mechanical allodynia by direct activation of microglia, which have enhanced inflammatory responses with TNF-α and IL-1β up-regulation. Thirdly, using single-nuclear RNA sequencing (snRNA-seq), we identified that Gal3 targets microglia and induces reprogramming of microglia, which may contribute to neuropathic pain establishment. Finally, Gal3 enhances excitatory synaptic transmission in excitatory neurons in the SDH via microglia activation. Our findings reveal that injured sensory neurons-derived Gal3 programs microglia in the SDH and contribute to neuropathic pain.

2023-08-14·International journal of molecular sciences

Epithelial Galectin-3 Induced the Mitochondrial Complex Inhibition and Cell Cycle Arrest of CD8⁺ T Cells in Severe/Critical COVID-19.

Article

作者: Wang, Yudie ; Yan, Qing ; Zhou, Jingjiao ; Wang, Yi ; Yang, Cheng ; Wang, Zhongyi ; Huang, Juan ; Liu, Yanping ; Feng, Ying

Previous research suggested that the dramatical decrease in CD8⁺ T cells is a contributing factor in the poor prognosis and disease progression of COVID-19 patients. However, the underlying mechanisms are not fully understood. In this study, we conducted Single-cell RNA sequencing (scRNA-seq) and single-cell T cell receptor sequencing (scTCR-seq) analysis, which revealed a proliferative-exhausted MCM⁺FASLG^low CD8⁺ T cell phenotype in severe/critical COVID-19 patients. These CD8⁺ T cells were characterized by G2/M cell cycle arrest, downregulation of respiratory chain complex genes, and inhibition of mitochondrial biogenesis. CellChat analysis of infected lung epithelial cells and CD8⁺ T cells found that the galectin signaling pathway played a crucial role in CD8⁺ T cell reduction and dysfunction. To further elucidate the mechanisms, we established SARS-CoV-2 ORF3a-transfected A549 cells, and co-cultured them with CD8⁺ T cells for ex vivo experiments. Our results showed that epithelial galectin-3 inhibited the transcription of the mitochondrial respiratory chain complex III/IV genes of CD8⁺ T cells by suppressing the nuclear translocation of nuclear respiratory factor 1 (NRF1). Further findings showed that the suppression of NRF1 translocation was associated with ERK-related and Akt-related signaling pathways. Importantly, the galectin-3 inhibitor, TD-139, promoted nuclear translocation of NRF1, thus enhancing the expression of the mitochondrial respiratory chain complex III/IV genes and the mitochondrial biogenesis of CD8⁺ T cells. Our study provided new insights into the immunopathogenesis of COVID-19 and identified potential therapeutic targets for the prevention and treatment of severe/critical COVID-19 patients.

项与 Olitigaltin 相关的新闻（医药）

2023-09-27

·FierceBiotech

Galecto lays off 70%, hunts for 'strategic alternatives' in wake of fibrosis drug fail

Galecto made no mention of whether its remaining clinical programs would be affected by the workforce restructuring or search for strategic alternatives. A month after halting work on an inhaled treatment for idiopathic pulmonary fibrosis in the wake of a phase 2 trial fail, Galecto is laying off 70% of its workforce as the Boston-based biotech mulls its options. The company has just completed a review of its business and is now conducting a “comprehensive exploration of strategic alternatives focused on maximizing shareholder value.” As is usual for biotechs in dire straits, the potential options include an acquisition, merger or yard sale of the company’s assets. Galecto made the usual caveat that it couldn’t guarantee that any transaction “will be completed on attractive terms, if at all.” But one thing that is for certain is that 29 employees—equivalent to 70% of the company’s entire workforce—will be heading out the door. The writing may have been on the wall for the biotech back in August, when Galecto announced that its small-molecule inhibitor of galectin-3, dubbed GB0139, failed to hit the trial’s primary endpoint of a demonstrating a slowing in decline in the volume of air exhaled from the lungs of patients with idiopathic pulmonary fibrosis. In fact, the average reduction in forced vital capacity was 316.6 ml among patients treated with a 3-mg daily dose of GB0139 for a year, compared to a less pronounced drop of 127.5 ml for those given placebo, meaning treated patients fared much worse. The drug had a bumpy ride to even get to this stage, with a data safety and monitoring board recommending in March 2021 that the company ax the 10-mg treatment arm after an “imbalance” in serious side effects was cropping up. With the 3-mg dose also coming up short last month, the biotech turned its attention to another galectin-3 inhibitor called GB1211, which is in development for liver cirrhosis. Galecto revealed at the time that it had recently wrapped a type C meeting with the FDA and was preparing for a placebo-controlled phase 2 trial in patients with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis that it planned to launch early next year. There’s also an OXL2 inhibitor called GB2064 in a phase 2 trial for myelofibrosis. In its postmarket release yesterday, the company made no mention of whether these plans would be affected by the workforce restructuring or search for strategic alternatives. With $52.1 million in the bank as of the end of June, Galecto CEO Hans Schambye, M.D., Ph.D., had previously said he was optimistic about securing fresh capital to progress the NASH prospect.

临床2期临床失败

2023-09-27

·Pharmaceutical Technology

Galecto downsizes by 70% following Phase II trial failure

Phalguni Deswal @Phalguni_GD The trial termination decimated the company’s stock, and it has not recovered since then. Image Credit: Buravleva stock / Shutterstock. Galecto has fired 70% of its workforce and is considering a whole list of strategic alternatives a month after announcing the failure of a trial with its lead drug. In August, the company’s lead candidate, GB0139, failed to meet its primary endpoint in the Phase II trial (NCT03832946) for the treatment of idiopathic pulmonary fibrosis (IPF). The trial termination decimated the company’s stock, and it has not recovered since then. Still, the 26 September restructuring news has revived the stock to a certain extent. Galecto’s stock was up by over 32% in pre-market trading today. Galecto’s market cap is $17.9m. The placebo-controlled Phase IIb had a lot of momentum, with the company having no issues with patient recruitment , even during the Covid-19 pandemic. However, all of this was for nought as the trial failed to show a change in the rate of decline of forced vital capacity, a measure of lung function, from baseline at 52 weeks. Galecto is now considering a merger, asset divestment or acquisition. The company was pragmatic regarding its options and noted that it does not expect any transaction to be “completed on attractive terms, if at all”. The US-based company is one in a growing list of companies that have downsized due to a multitude of reasons that range from low funding, US Food and Drug Administration (FDA) rejections or decreased sales forecasts for marketed products. Other drugs in Galecto’s pipeline include GB1211, which is being evaluated in an open-label Phase II trial (NCT05240131) as a combination therapy with Roche’s Tecentriq (atezolizumab) for non-small cell lung cancer (NSCLC). GB2064 is being evaluated in an open-label Phase IIa trial (NCT04679870) investigating myelofibrosis , a rare blood cancer. The topline results from the trial are expected by the end of 2023. Galecto also received FDA approval to start a Phase IIa trial for GB1211, an oral galectin-3 inhibitor for the treatment of patients with decompensated non-alcoholic steatohepatitis (NASH) cirrhosis, although the company pointed out that the trial initiation will be contingent on securing additional funding.

临床2期并购临床失败IPO

2023-09-26

·Firstwordpharma

Galecto to eliminate 70% of workforce

Galecto disclosed Tuesday that it plans to explore strategic alternatives for the business, including an acquisition, merger or divestiture. It also intends to implement a restructuring plan that includes reducing its workforce by about 29 people, or approximately 70% of its existing headcount. Company shares gained as much as 40% in after-hours trade.The move follows its decision in August to end development of its GB0139 drug candidate in idiopathic pulmonary fibrosis (IPF) after it failed the Phase IIb GALACTIC-1 study. Following the readout, CEO Hans Schambye said the company would be evaluating resource allocation with the goal of extending its cash runway into 2025.Analysts at H. C. Wainwright & Co. suggested at the time that there "[remained] intrinsic value in the Galecto pipeline," and that the decision to scrap GB0139 "ought not to have read-through to Galecto's other clinical-stage programmes. These assets do not share a molecular structure with GB0139 and are aimed at indications unrelated to IPF; namely, decompensated liver cirrhosis and myelofibrosis."In its statement on Tuesday, Galecto said there was no guarantee that its exploration would lead to it pursuing a transaction; or if pursued, that any transaction would be completed on attractive terms. It has also not set a timetable for completion of its evaluation process, nor does it plan to disclose further developments or guidance on the status of its programmes until it deems necessary.As of June 30, Galecto said its cash, cash equivalents and investments balance stood at $52.1 million.

临床2期IPO临床失败

100 项与 Olitigaltin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12895

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特发性肺纤维化	临床1期	格鲁吉亚	Galecto Biotech ApS	-
新型冠状病毒感染	药物发现	英国	The University of Edinburgh	2020-06-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02257177 (Pubmed \| Clin Chest Med)	临床1期	特发性肺纤维化	60	TD139	(製壓觸壓鹽膚簾壓窪蓋) = 鏇窪鏇衊積艱顧鏇築鏇積蓋淵艱築製膚淵鹹觸 (構憲齋窪積顧製襯遞獵 ) 更多	-	2020-11-19
ARVO2014	N/A	角膜纤维化	-	TD139	鑰繭窪壓鏇艱觸壓範鏇(餘夢製膚廠鹹鹽鑰簾蓋) = 遞糧繭觸壓憲鹹淵襯簾鬱範淵積獵夢襯廠醖膚 (繭餘鹽鏇餘觸簾膚網窪 ) 更多	-	2014-04-01
				Vehicle	鑰繭窪壓鏇艱觸壓範鏇(餘夢製膚廠鹹鹽鑰簾蓋) = 窪獵簾觸鬱網蓋醖醖鹹鬱範淵積獵夢襯廠醖膚 (繭餘鹽鏇餘觸簾膚網窪 ) 更多
NCT04473053 (DEFINE, Corporate Publications) 人工标引	临床1/2期	新型冠状病毒感染	41	Standard of Care+GB0139	(簾鹽窪艱選襯膚積獵蓋) = 繭鏇淵願窪蓋廠艱襯簾壓獵鹹顧範壓醖壓醖範 (餘構願廠顧選網衊繭醖 ) 更多	积极	2021-06-22
				Standard of Care	-